Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

NCT03255083 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT03255083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03255083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Terminated
Start date
April 10, 2019
Completion date
September 4, 2020
Enrollment
13 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)